Replidyne, Inc.

As of February 25, 2009, Replidyne, Inc. was acquired by Cardiovascular Systems Inc., in a reverse merger transaction.

Replidyne, Inc., a biopharmaceutical company, engages in discovering, developing, in-licensing, and commercializing anti-infective products. Its product candidate and development program portfolio consists of faropenem medoxomil, an oral community antibiotic that is in Phase III clinical trials for the treatment of acute bacterial sinusitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis, and uncomplicated skin and skin structure infections in adults; and REP3123, an investigational narrow-spectrum antibacterial agent, which has completed preclinical studies for the treatment of Clostridium difficile (C. difficile) bacteria and C. difficile-associated disease. The company also develops faropenem medoxomil oral liquid formulation, which has completed Phase II clinical trials for pediatric use; and assays that identify compounds that inhibit bacterial DNA replication. It has a license agreement with Daiichi Asubio Pharma Co., Ltd. to develop and commercialize various forms of faropenem medoxomil for adult and pediatric use in the United States and Canada. The company was founded in 2000 and is headquartered in Louisville, Colorado.